anti-anhedonia

why it works

Anhedonia is the inability to feel joy, pleasure or interest in previously enjoyed activities, and it is worth defining because it is not the same as low mood and does not respond to the same things.

⚠️ THE FIRST THING WORTH SAYING IS NOT PHARMACOLOGICAL. Meditation, new habits and new experiences are worth trying before any drug-oriented option, and finding a deeper meaning matters more than any compound on this list. Recommending research agents for this purpose is not a comfortable thing to do, and that discomfort is worth stating rather than hiding behind a mechanism.

GB-115 is the foundation. It blocks cholecystokinin receptors, which sit behind panic, stress and low-motivation states, and it reduces anxiety while improving mental clarity and processing speed rather than at their expense. It is reported to normalise the HPA axis, balancing cortisol and DHEA, and to carry anti-inflammatory activity via kappa opioid receptor modulation. Reports of it aiding emotional numbness and restoring a sense of meaning are what put it first here.

J-147 is the metabolic resilience piece, and the reason it belongs is that anhedonia is not always a dopamine story. It enhances ATP synthase activity directly and raises BDNF and NGF, with anti-anxiety and antidepressant-like effects in its own literature.

9-Me-BC is the dopamine piece, and it is most relevant where the anhedonia is tied to stimulant tolerance, low drive or reward-system burnout. It promotes dopaminergic neuron function and upregulates tyrosine hydroxylase. L-Tyrosine is its substrate and the two belong together.

how they work together

Anhedonia is treated here as three separable failures rather than one, and each item answers a different one. That framing is the stack's actual argument.

The first is stress load. GB-115 blocks CCK1 receptors and is reported to normalise HPA axis activity, and emotional blunting frequently comes from sustained stress rather than from a broken reward system; removing the pressure is upstream of everything else here.

The second is metabolic. Reward processing is energetically expensive, and a brain that is metabolically tired feels emotionally underpowered even when nothing else is wrong. J-147 acts directly on ATP synthase and separately raises BDNF and NGF, so it addresses both the energy and the trophic side.

The third is dopaminergic, and the design decision worth noting is that the goal is explicitly not to force a dopamine spike. 9-Me-BC raises tyrosine hydroxylase, the rate-limiting enzyme, which changes the system's capacity rather than dumping its contents; L-tyrosine supplies that enzyme's substrate. Raising the rate-limiting enzyme without supplying what it acts on is half a mechanism, which is why the two are paired.

what it feels like

Weeks, not days, and the honest expectation is a return toward baseline rather than a lift above it. What people report first is usually not pleasure returning but the flatness thinning: music being worth putting on, a conversation being worth having.

J-147 and GB-115 are both slow. 9-Me-BC is reported as gradual rather than acute, which is consistent with a mechanism that changes synthesis capacity rather than release.

If this produces a noticeable euphoria, something other than the stated mechanism is happening.